WO2006020557A2 - Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer - Google Patents

Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer Download PDF

Info

Publication number
WO2006020557A2
WO2006020557A2 PCT/US2005/028100 US2005028100W WO2006020557A2 WO 2006020557 A2 WO2006020557 A2 WO 2006020557A2 US 2005028100 W US2005028100 W US 2005028100W WO 2006020557 A2 WO2006020557 A2 WO 2006020557A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
seq
cells
amino acid
gpr56
Prior art date
Application number
PCT/US2005/028100
Other languages
English (en)
Other versions
WO2006020557A3 (fr
Inventor
Henry Qi-Xian Li
Ning Ke
Mirta Grifman
Wufang Fan
Yu Dehua
Flossie Wong-Staal
Original Assignee
Immusol, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol, Inc. filed Critical Immusol, Inc.
Publication of WO2006020557A2 publication Critical patent/WO2006020557A2/fr
Publication of WO2006020557A3 publication Critical patent/WO2006020557A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne, de manière générale, des procédés d'inhibition de la croissance de cellules cancéreuses ou de tumeurs. Cette invention concerne également l'identification d'agents utiles dans le traitement du cancer. Ces procédés impliquent généralement le ciblage de deux gènes ou de leurs protéines codées, GPR56 ou DNER.
PCT/US2005/028100 2004-08-10 2005-08-09 Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer WO2006020557A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60064704P 2004-08-10 2004-08-10
US60/600,647 2004-08-10

Publications (2)

Publication Number Publication Date
WO2006020557A2 true WO2006020557A2 (fr) 2006-02-23
WO2006020557A3 WO2006020557A3 (fr) 2007-08-16

Family

ID=35908070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028100 WO2006020557A2 (fr) 2004-08-10 2005-08-09 Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer

Country Status (1)

Country Link
WO (1) WO2006020557A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012157589A1 (fr) * 2011-05-13 2012-11-22 国立大学法人宮崎大学 Inhibiteur d'adhérence cellulaire, inhibiteur de prolifération cellulaire, et méthode et trousse pour le dépistage du cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167485A1 (en) * 1997-09-24 2003-09-04 Garvan Institute Of Medical Research Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
US20030175209A1 (en) * 2001-12-27 2003-09-18 Sabine Mueller Use of biomolecular targets in the treatment and visualization of tumors
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030167485A1 (en) * 1997-09-24 2003-09-04 Garvan Institute Of Medical Research Novel G protein-coupled receptor encoding gene and diagnostic uses therefor
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20030175209A1 (en) * 2001-12-27 2003-09-18 Sabine Mueller Use of biomolecular targets in the treatment and visualization of tumors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012157589A1 (fr) * 2011-05-13 2012-11-22 国立大学法人宮崎大学 Inhibiteur d'adhérence cellulaire, inhibiteur de prolifération cellulaire, et méthode et trousse pour le dépistage du cancer
JP6029019B2 (ja) * 2011-05-13 2016-11-24 国立大学法人 宮崎大学 細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット

Also Published As

Publication number Publication date
WO2006020557A3 (fr) 2007-08-16

Similar Documents

Publication Publication Date Title
AU2021204818B2 (en) Methods to eliminate cancer stem cells by targeting cd47
US6919176B2 (en) Polypeptides and nucleic acids associated with cancer
US20070184459A1 (en) Methods of inhibiting cancer growth by binding to nuclear receptors
Yang et al. Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism
KR20210111176A (ko) 항암제 내성 진단 또는 치료용 조성물
ES2800328T3 (es) Métodos para diagnosticar y tratar la leucemia linfocítica crónica de linfocitos B en base a la detección e inhibición de CD84
JP2020095046A (ja) 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価
US20070087984A1 (en) Method of identifying agents that inhibit the growth of cancer cells
WO2006020557A2 (fr) Procedes d'utilisation ou d'identification d'agents inhibant la croissance d'un cancer
US20110027297A1 (en) Methods Involving MS4A12 and Agents Targeting MS4A12 for Therapy, Diagnosis and Testing
US20190203302A1 (en) Biomarker composition comprising lrp-1 as active ingredient, for diagnosis of radiation-resistant cancer or prediction of radiation therapy prognosis
WO2010008084A1 (fr) Nouvelle application d'utilisation de récepteur reconnaissant une chaîne de sucre
WO2005017112A2 (fr) Methodes d'inhibition de la croissance cancereuse par liaison a des recepteurs nucleaires
KR20210156849A (ko) Gpcr 헤테로머 저해제들 및 이의 용도
JP2011502108A (ja) 癌の予防・治療剤
JP2016104716A (ja) 膵臓癌治療用のｃｄ９５シグナル伝達阻害化合物
EP1788390A1 (fr) Methode de criblage
WO2005120520A2 (fr) Compositions et procedes de diagnostic et de traitement de maladies neoplastiques chimioresistantes
JPWO2008102777A1 (ja) インスリン抵抗性改善剤
WO2008005769A2 (fr) Procédés d'inhibition de la réplication du vhc
US20120121610A1 (en) Therapeutic agent and assay
WO2006019429A2 (fr) Procedes d'identification et d'utilisation d'agents accroissant l'inhibition de l'infection au hcf ou la resistance a celle-ci
WO2010147274A1 (fr) Granules sécrétoires et facteurs granulogènes en tant que cible d'un traitement anticancéreux
Seyed Sadr SLIT proteins inhibit malignant brain tumour cell invasion via downregulation of pro-invasive genes
JP2011105669A (ja) 抗腫瘍剤および抗腫瘍剤のスクリーニング方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase